Abstract Cyclin-dependent kinase 4 (CDK4) and CDK6 are critical mediators of cellular
transition into S phase and are important for the initiation, growth and survival of many …

Uncontrolled cellular proliferation, mediated by dysregulation of the cell-cycle machinery
and activation of cyclin-dependent kinases (CDKs) to promote cell-cycle progression, lies at …

CDK4/6 inhibition with endocrine therapy is now a standard of care for advanced estrogen
receptor–positive breast cancer. Mechanisms of CDK4/6 inhibitor resistance have been …

Abstract Cyclin-dependent kinase (CDK) 4/6 inhibition in combination with endocrine
therapy is the standard-of-care treatment for patients with advanced-stage hormone receptor …

Osteosarcoma is the most common primary malignancy of bone in children and young
adults. This tumor has a very heterogeneous genetic profile and lacks any consistent …

Pharmacological inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are now an
established standard of care for patients with advanced hormone receptor-positive breast …

Using transgenic mouse models, cell line-based functional studies, and clinical specimens,
we show that cyclin D1/CDK4 mediate resistance to targeted therapy for HER2-positive …

Aberrant expression of programmed death ligand-1 (PD-L1) in tumor cells promotes cancer
progression by suppressing cancer immunity. The retinoblastoma protein RB is a tumor …

The precise timing of cell cycle gene expression is critical for the control of cell proliferation;
de-regulation of this timing promotes the formation of cancer and leads to defects during …

Posttranslational modifications (PTMs) of proteins, the major mechanism of protein function
regulation, play important roles in regulating a variety of cellular physiological and …